Souzan Sanati
Cedars-Sinai Medical Center(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Breast Lesions and Carcinomas, Cancer Genomics and Diagnostics
Most-Cited Works
- → Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)(2017)405 cited
- → NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer(2017)371 cited
- → Proteogenomic integration reveals therapeutic targets in breast cancer xenografts(2017)153 cited
- → Improved laboratory resource utilization and patient care with the use of rapid on‐site evaluation for endobronchial ultrasound fine‐needle aspiration biopsy(2013)83 cited
- → A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA -Mutant ER-Positive and HER2-Negative Breast Cancer(2017)73 cited
- → Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib(2017)70 cited
- → Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer(2016)64 cited
- → Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast(2018)63 cited
- → Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study(2021)56 cited
- → ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.(2020)45 cited